{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030944","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.447778+00:00","generated_at":"2026-06-08T08:44:20.324496+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyadic Q3 revenue $397K (-55% YoY); cash $8.2M; Phase 1 top-line results expected Dec 2023","bullets":["Revenue $397K vs $880K YoY; net loss $1.614M ($0.06) vs $1.809M ($0.06).","Cash $8.2M as of Sep 30, down from $12.7M at Dec 31, 2022.","Received $0.6M upfront in Oct for Dapibus animal-free dairy enzyme license.","DYAI-100 Phase 1 top-line results expected Dec 2023; no major safety concerns.","New collaboration with Mass General/DoD ($5.88M grant) and bYoRNA for mRNA."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030944","json":"https://secwatch.observer/filing/0001437749-23-030944.json","markdown":"https://secwatch.observer/filing/0001437749-23-030944.md","text":"https://secwatch.observer/filing/0001437749-23-030944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923030944/0001437749-23-030944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923030944/dyai20230825_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:44:20.324496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}